Bypassing agent regimens and costs for prophylaxis in patients with inhibitors

被引：0
|
作者：
Gringeri, A. [1 ,2 ]
机构：
[1] IRCCS Maggiore Policlin, Dept Med & Med Special, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, Regina Elena Hosp Fdn, I-20122 Milan, Italy
[2] Univ Milan, Milan, Italy
来源：
HAEMOPHILIA | 2009年 / 15卷 / 06期
关键词：
HEMOPHILIA-A;
D O I：
10.1111/j.1365-2516.2009.02068.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1337
页数：2
相关论文
共 50 条
  • [21] Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients With Hemophilia Having Inhibitors
    Ay, Yilmaz
    Balkan, Can
    Karapinar, Deniz Yilmaz
    Akin, Mehmet
    Bilenoglu, Basri
    Kavakli, Kaan
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (04) : 389 - 394
  • [22] Bypassing Agents and Thromboembolic Events in Patients with Hemophilia and Inhibitors
    Bykov, Katsiaryna
    Bohn, Rhonda L.
    Ewenstein, Bruce M.
    Seeger, John D.
    Avorn, Jerry
    Bateman, Brian T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 191 - 192
  • [23] Episodic treatment with bypassing agent has high bleed rates and worsening joint scores in Hemophilia patients with inhibitors
    Sidharthan, Neeraj
    Mathew, Sheena
    Paul, Linny
    Bernard, Jayamma
    Prabhakaran, Arundhathi
    Viswam, Dinkar
    Glady, Shainy
    Soman, Sumi
    Pillai, Vijayakumar Narayana
    HAEMOPHILIA, 2020, 26 : 31 - 32
  • [24] Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study
    Callaghan, Michael U.
    Negrier, Claude
    Young, Guy
    Khoo, Liane
    Mahlangu, Johnny
    Windyga, Jerzy
    Oldenburg, Johannes
    Xu, Jin
    Catalani, Olivier
    Asikanius, Elina
    Adamkewicz, Joanne I.
    Shima, Midori
    BLOOD, 2017, 130
  • [25] Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent
    Takedani, H.
    Hirose, J.
    Minamoto, F.
    Kubota, M.
    Kinkawa, J.
    Noguchi, M.
    HAEMOPHILIA, 2016, 22 (05) : E459 - E461
  • [26] The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors
    Ju, Hee Young
    Jang, Hye Lim
    Park, Young Shil
    BLOOD RESEARCH, 2015, 50 (03) : 173 - 178
  • [27] Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance During Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study
    Callaghan, M.
    Negrier, C.
    Young, G.
    Khoo, L.
    Mahlangu, J.
    Windyga, J.
    Oldenburg, J.
    Xu, J.
    Catalani, O.
    Asikanius, E.
    Adamkewicz, J.
    Shima, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 129 - 129
  • [28] Prophylaxis in haemophilia patients with inhibitors
    Leissinger, C. A.
    HAEMOPHILIA, 2006, 12 : 67 - 72
  • [29] Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients
    Ewenstein, Bruce M.
    Wong, Wing-Yen
    Schoppmann, Axel
    THROMBOSIS RESEARCH, 2011, 127 (02) : 174 - 175
  • [30] Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens
    Watt, Maureen
    Epstein, Josh
    Xuan, Dennis
    BLOOD, 2018, 132
12345